| Ytd | -73.71% | |
| 1y | -54.00% |
| Open | 0.39 | Prev Close | 0.38 | Low | 0.37 | High | 0.40 | Mkt Cap | 35.50M |
| Vol | 821.85K | Avg Vol | 2.85M | EPS | -0.48 | P/E | N/A | Forward P/E | -3.38 |
| Beta | 1.74 | Short Ratio | 2.79 | Inst. Own | 76.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 0.57 | 200-d Avg | 1.66 | 1yr Est | 7.70 |
CNTX News
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates
Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipel
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the a
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected begi
PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-sta
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lo
Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLD
Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc
29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian canc
PHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”
Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up,
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the ana
Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-st
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC
Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) has been given a consensus recommendation
Galectin Therapeutics (NASDAQ: GALT - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get
Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintai
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight a
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the a
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a inte
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Compan
Context Therapeutics (NASDAQ: CNTX) CEO Martin Lehr outlined the company's strategy and upcoming cli
Shares of Context Therapeutics Inc. (NASDAQ: CNTX - Get Free Report) have been assigned an average r
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get F
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Context Therapeutics (NASDAQ: CNTX - Get Free Rep
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy an
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the a
D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy an
Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-sta
Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with
Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy